Research and development(R&D)
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor developed for treating anemia associated with chronic kidney disease. Its core process involves inhibiting PHD enzymes to stabilize HIF-1α, thereby stimulating endogenous erythropoietin production. The compound features the molecular formula <strong>C<sub>20</sub>H<sub>24</sub>N<sub>6</sub>O<sub>3</sub></strong> and CAS number <strong>975637-87-3</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Hematology:</strong> Management of anemia in non-dialysis dependent CKD patients.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> Active Pharmaceutical Ingredient (API) synthesis for oral anemia therapies.</li>
<li><strong>Research:</strong> Clinical trials investigating ischemic diseases and hypoxia-related pathologies.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated for patients with uncontrolled hypertension or history of thromboembolic events. Requires storage in sealed containers at controlled room temperature away from moisture. Handling must adhere to occupational safety guidelines for novel small molecule inhibitors.</p>